IDEXX Laboratories, Inc.
IDXX
$504.70
-0.36%
IDEXX Laboratories, Inc. is a global leader in veterinary diagnostics, providing in-office test kits, benchtop analyzers, reference laboratory services, and practice management software for veterinarians and livestock producers. The company holds a dominant market position in companion animal diagnostics, differentiated by its integrated diagnostic ecosystem and recurring revenue model. The current investor narrative centers on the company's ability to sustain growth amid a post-pandemic normalization in pet healthcare spending, with recent quarterly results showing strong revenue growth and raised guidance, though the stock has faced significant downward pressure over the past year, raising questions about valuation and market sentiment.…
IDXX
IDEXX Laboratories, Inc.
$504.70
Related headlines
IDXX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IDEXX Laboratories, Inc.'s 12-month outlook, with a consensus price target around $698.92 and implied upside of +38.5% versus the current price.
Average Target
$698.92
0 analysts
Implied Upside
+38.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$470 - $805
Analyst target range
IDEXX has coverage from 13 analysts, with a consensus recommendation of 'Buy' and a mean rating of 2.21 (where 1 is Strong Buy and 5 is Sell). The average target price is $698.92, implying a 30.5% upside from the current price of $535.38. The distribution includes 5 Buy ratings, 5 Overweight ratings, and 3 Neutral ratings, with no Sell ratings, indicating a bullish sentiment. The target price range spans from a low of $470.00 to a high of $805.00, reflecting a wide dispersion of 71% between the low and high targets. The high target assumes continued strong growth and multiple expansion, while the low target suggests concerns about valuation compression or slower growth. Recent ratings actions have been predominantly positive, with firms like Stifel, BTIG, and Morgan Stanley maintaining Buy or Overweight ratings, while UBS and Piper Sandler remain Neutral, showing a balanced but optimistic outlook.
Drowning in data?
Find the real signal!
Bulls vs Bears: IDXX Investment Factors
IDEXX presents a compelling bull case driven by accelerating revenue growth, expanding margins, and a dominant market position, supported by a consensus Buy rating and 30.5% average upside. However, the bear case is equally strong, centered on a premium valuation that leaves little room for error, persistent underperformance versus the market, and the risk of post-pandemic demand normalization. The most critical tension is whether IDEXX can sustain its double-digit growth to justify its 51x trailing PE; if growth decelerates, the stock could face significant de-rating, while continued acceleration could drive it toward the high end of analyst targets. Currently, the evidence slightly favors the bulls given the strong Q1 results and raised guidance, but the valuation risk warrants caution.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 14.26% YoY to $1.14B, a sharp acceleration from the 4.5% growth in Q1 2025, signaling strong demand for IDEXX's diagnostic products and services. This momentum is supported by higher clinical visits and increased diagnostic frequency, as highlighted in the company's raised guidance.
- Expanding Profitability: Gross margin improved to 63.35% from 62.44% a year ago, and operating margin expanded to 31.78% from 31.70%, reflecting operational efficiency and pricing power. Net margin held steady at 24.4%, demonstrating the company's ability to convert revenue growth into bottom-line gains.
- Dominant Market Position: IDEXX is the global leader in veterinary diagnostics with an integrated ecosystem of in-office analyzers, reference lab services, and practice management software. This moat creates high switching costs for veterinarians and supports recurring revenue, underpinning long-term growth.
- Analyst Consensus Buy: With 13 analysts covering the stock, the consensus is 'Buy' with a mean rating of 2.21 and an average target price of $698.92, implying 30.5% upside from the current price of $535.38. No Sell ratings exist, and recent actions from Stifel, BTIG, and Morgan Stanley have been positive.
Bearish
- Significant Underperformance: The stock has declined 16.4% over the past year while the S&P 500 gained 18.65%, resulting in a relative strength of -35.05%. This persistent underperformance indicates waning investor confidence and potential sector rotation away from high-multiple healthcare names.
- Premium Valuation: IDEXX trades at a trailing PE of 51.37x and a forward PE of 31.98x, a 134% premium to the industry average of 22x. Even with strong growth, the PEG ratio of 2.31 suggests the market is pricing in aggressive expectations that leave little room for error.
- Post-Pandemic Normalization: The surge in pet adoption during the pandemic has subsided, leading to a normalization in pet healthcare spending. Q1 2025's modest 4.5% growth highlighted this slowdown, and any further deceleration could pressure revenue and justify a lower multiple.
- High Beta and Volatility: With a beta of 1.538, IDEXX is significantly more volatile than the market, amplifying downside risk during broader sell-offs. The stock's 31.34% max drawdown over the past year underscores this sensitivity, which could deter risk-averse investors.
IDXX Technical Analysis
IDEXX is in a clear downtrend over the past year, with the stock price declining 16.4% over the last 12 months, while the S&P 500 gained 18.65% during the same period. The current price of $535.38 sits near the lower end of its 52-week range, at approximately 22% above the 52-week low of $518.55 and 30% below the 52-week high of $769.98. This positioning suggests the stock is trading near support levels, but the persistent underperformance relative to the market indicates ongoing selling pressure and a lack of bullish conviction.
Beta
1.54
1.54x market volatility
Max Drawdown
-34.2%
Largest decline past year
52-Week Range
$501-$770
Price range past year
Annual Return
-21.8%
Cumulative gain past year
| Period | IDXX Return | S&P 500 |
|---|---|---|
| 1m | -11.5% | -1.1% |
| 3m | -10.0% | +3.0% |
| 6m | -12.0% | +15.4% |
| 1y | -21.8% | +16.2% |
| ytd | -24.7% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IDXX Fundamental Analysis
IDEXX's revenue trajectory remains robust, with the most recent quarter (Q1 2026) reporting revenue of $1.14082 billion, a 14.26% year-over-year increase, accelerating from the 4.5% growth seen in Q1 2025. This growth is driven by both product revenue of $666.124 million and service revenue of $474.696 million, reflecting strong demand for diagnostics. The company's net income for Q1 2026 was $278.446 million, with a net margin of 24.4%, up from 24.3% in the prior year quarter, indicating stable profitability. Gross margin improved to 63.35% from 62.44% a year ago, while operating margin expanded to 31.78% from 31.70%, showcasing operational efficiency. IDEXX maintains a healthy balance sheet with a debt-to-equity ratio of 0.671 and a current ratio of 1.167, though free cash flow for Q1 2026 was $234.264 million, down from $207.936 million in Q1 2025, reflecting increased capital expenditures and working capital needs.
Quarterly Revenue
$1.1B
2026-03
Revenue YoY Growth
+14.3%
YoY Comparison
Gross Margin
63.3%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IDXX Overvalued?
Given IDEXX's positive net income, the PE ratio is the primary valuation metric. The trailing PE stands at 51.37x, while the forward PE is 31.98x, indicating the market expects significant earnings growth. The gap between trailing and forward PE suggests an anticipated EPS increase of over 60%, which aligns with the company's raised guidance. Compared to the industry average PE of 22x (from valuation data), IDEXX trades at a 134% premium, reflecting its superior growth and profitability. Historically, IDEXX's PE has ranged from 35x to 85x over the past five years, with the current trailing PE of 51.37x near the lower end of that range, suggesting the stock may be undervalued relative to its own history if growth persists.
PE
51.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 35x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
37.5x
Enterprise Value Multiple